Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review.

ABSTRACT: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and most NSCLC is diagnosed in the advanced stage. The advent of immune check point inhibitors (ICIs) changed the therapeutic scenario both in metastatic disease (in first and subsequent lines) and earlier settings. Comorbidities, reduced organ function, cognitive deterioration, and social impairment give reasons for a greater probability of adverse events, making the treatment of elderly patients challenging. The reduced toxicity of ICIs compared to standard chemotherapy makes this approach attractive in this population. The effectiveness of ICIs varies according to age, and patients older than 75 years may benefit less than younger pa

SUBMITTER: Montrone M 

PROVIDER: S-EPMC10003062 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature